Key points that many forget about, ignore, or simply don't know about:
Brilacidin is one of the few drugs targeting COVID-19 that has been tested in human trials (a total of 8) for other clinical indications, providing an established safety and efficacy database on over 460 subjects, thereby potentially enabling it to rapidly help address the novel coronavirus crisis.
COMBINE WITH THIS:
June 17, 2020 Innovation Pharmaceuticals’ Brilacidin Inhibits SARS-CoV-2 (COVID-19) by 97 Percent in a Human Lung Cell Line Brilacidin Data from Ongoing Testing at U.S. Regional Biocontainment Laboratory